Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
Featured News from MarketBeat.com Biotech Breakouts: 3 Stocks With Massive Upside PotentialWritten by Chris Markoch. Published 9/17/2025. 
Key Points - Viking stock is down, but still has major upside in the obesity drug market.
- ImmunityBio advances Anktiva beyond bladder cancer with new trial results.
- Maze Therapeutics rallies on early-stage data with more catalysts ahead.
Investing in biotechnology stocks can be challenging because of the complex science behind drug candidates. These shares often see double-digit swings in either direction, making them highly volatile. Yet for long-term investors willing to endure the clinical trial process, biotech stocks offer an attractive risk-reward profile. The potential payoff from the three companies profiled below could be substantial for those who hold through key trial milestones. Viking: An Obesity Challenger with Big Upside what I just learned about what's unfolding in the White House is truly stunning…
And you need to see it for yourself.
Once you see what's unfolding behind the scenes, you'll understand why I rushed this interview and opportunity to you today. Click here to watch this video Viking Therapeutics Inc. (NASDAQ: VKTX) rallied in 2024 on the strength of GLP-1 weight-loss drug enthusiasm but has slid over 40% so far in 2025, including a 20% drop after its August clinical update. The data weren't disastrous—patients lost an average of 12.2% of their body weight—so the trial cannot be deemed a failure. Investors fretted that top-line losses emerged only at the highest dose, unlike competitors who reported similar or better results at lower doses. A 28% dropout rate also hinted at tolerability issues. Was a nearly 50% sell-off justified? Many analysts say no. They've set a consensus price target of $87.50, implying roughly 270% upside from current levels. The obesity drug market is vast enough to support more than just the industry giants (Novo Nordisk and Eli Lilly). Technically, VKTX appears to be bottoming: its relative strength index (RSI) sits near 34—approaching oversold territory—and the MACD shows waning bearish momentum. After a late-August death cross, a golden cross would signal renewed strength. 
ImmunityBio: A Penny Stock with Serious Potential ImmunityBio Inc. (NASDAQ: IBRX) is up about 8.4% in 2025, with most gains arriving over the past month. In late August, all five patients in its pilot glioblastoma study achieved 100% disease control using a regimen that includes ANKTIVA. Approved by the FDA in April 2024 for bladder cancer, ANKTIVA is now in trials for other cancers and is being evaluated as a potential therapy for HIV and Long COVID. This broad utility makes it one of the most intriguing immunotherapy assets in development. Analysts have set a consensus price target of $10.75, suggesting over 280% upside. That said, IBRX trades above its 200-day SMA and carries an RSI near 76, indicating it may be overbought in the short term. A modest pullback could offer a better entry for patient investors. 
Maze Therapeutics: Early Success in Rare Diseases Maze Therapeutics Inc. (NASDAQ: MAZE) began trading in February 2025 and has already rallied roughly 86%. Analysts believe additional gains lie ahead. On Sept. 11, Maze announced positive Phase 1 results for its lead candidate, MZE782. This oral SLC6A19 inhibitor showed proof of mechanism as a potential treatment for phenylketonuria (PKU) and chronic kidney disease (CKD), clearing the path to Phase 2. While FDA approval remains years away, HC Wainwright leads the bullish pack with a $50 price target, implying roughly 2× upside. MAZE's RSI is approaching overbought, but it recently found support near $22.40—confirmation of which would signal continued momentum for bulls. Maze offers exposure to rare-disease therapeutics, a biotech niche known for strong pricing power and limited competition. Continued clinical progress could translate into sustained stock gains. 
| 
